|
Designs with maximal power of detecting the interaction, according to sensitivity and specificity |
|||||||||
| Gene-surrogate |
Flexible two-phase design options |
Expected Phase One counts |
Power# |
Cost* |
|||||
|
|
|||||||||
| Spec |
Sens |
n0 |
n1 |
ρ0† |
ρ1‡ |
N0 |
N1 |
||
|
|
|||||||||
| 70% |
80% |
800 |
400 |
90% |
90% |
5902 |
1373 |
83% |
1564 |
| 70% |
90% |
800 |
400 |
90% |
90% |
5882 |
1325 |
87% |
1560 |
| 80% |
60% |
800 |
400 |
90% |
90% |
8824 |
1988 |
87% |
1741 |
| 80% |
70% |
800 |
400 |
90% |
90% |
8780 |
1889 |
91% |
1733 |
| 80% |
80% |
800 |
400 |
90% |
90% |
8738 |
1800 |
94% |
1727 |
| 80% |
90% |
800 |
400 |
90% |
90% |
8696 |
1718 |
96% |
1720 |
| 90% |
60% |
900 |
300 |
90% |
90% |
19286 |
2000 |
98% |
2264 |
| 90% |
70% |
900 |
300 |
90% |
90% |
19104 |
2000 |
99% |
2255 |
| 90% |
80% |
900 |
300 |
90% |
90% |
18925 |
1960 |
99.6% |
2244 |
| 90% |
90% |
900 |
300 |
90% |
90% |
18750 |
1835 |
99.8% |
2229 |
Wild et al. Epidemiologic Perspectives & Innovations 2008 5:4 doi:10.1186/1742-5573-5-4 |
|||||||||